Provention Bio, Inc. is dedicated to the mission of intercepting and preventing immune-mediated disease through the sourcing, development and commercialization of novel therapeutics and cutting edge solutions.
Instead of “running with the herd” to develop therapeutics that treat the advanced stages and symptoms of autoimmune and inflammatory diseases after they’ve emerged, Provention is taking a path less travelled, by pre-empting, slowing and reversing the progression of chronic diseases and developing technologies that intervene before the targeted disease begins, re-appears or progresses. This innovative approach, offers the potential to reduce the high morbidity, mortality, patient suffering, and escalating costs of chronic autoimmune and inflammatory diseases, such as type 1 diabetes (T1D), Crohn’s disease, and ulcerative colitis, and emerging viral infections.
The experience, knowledge and creativity of Provention’s leadership team empowers us with a singular clinical vision focused on disease interception and prevention. Rather than treating these devastating diseases after they have become irreversible, life-altering conditions, Provention is seeking to identify and prevent the underlying cause or trigger of such diseases before symptoms emerge and to intercept disease progression or relapse to eliminate long-term damage and chronic suffering.
Provention’s scientific founder, Dr. Francisco Leon, and I, along with our colleagues, partners and consultants, could not be more committed to the pursuit and realization of our vision of intercepting and preventing immune-mediated disease. We are grateful for the support of our investors, collaborators and, most importantly, the patients that are afflicted by the diseases we are targeting, whose hope, courage and tenacity humble and inspire us every day.
Chief Executive Officer
Provention Bio, Inc.